Claims for Patent: 11,097,063
✉ Email this page to a colleague
Summary for Patent: 11,097,063
Title: | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Abstract: | A syringe device for ejecting a dose of a medicament, the syringe device comprising: a dose limiting mechanism arranged to interact with a dose ejecting mechanism to prevent ejection of a dose exceeding a set dose, and a safety mechanism, which is arranged such with respect to the dose ejecting mechanism that, if the dose limiting mechanism fails, the safety mechanism prevents ejection of a dose exceeding the set dose. |
Inventor(s): | Eiland Jacob, Enggaard Christian Peter, Moeller Claus Schmidt, Markussen Tom Hede |
Assignee: | Novo Nordisk A/S |
Application Number: | US16250620 |
Patent Claims: |
Details for Patent 11,097,063
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc. | LEVEMIR | insulin detemir | Injection | 021536 | June 16, 2005 | 11,097,063 | 2039-01-17 |
Novo Nordisk Inc. | LEVEMIR | insulin detemir | Injection | 021536 | October 31, 2013 | 11,097,063 | 2039-01-17 |
Novo Nordisk Inc. | TRESIBA | insulin degludec | Injection | 203314 | September 25, 2015 | 11,097,063 | 2039-01-17 |
Novo Nordisk Inc. | TRESIBA | insulin degludec | Injection | 203314 | November 21, 2018 | 11,097,063 | 2039-01-17 |
Novo Nordisk Inc. | FIASP | insulin aspart | Injection | 208751 | September 29, 2017 | 11,097,063 | 2039-01-17 |
Novo Nordisk Inc. | FIASP | insulin aspart | Injection | 208751 | September 24, 2018 | 11,097,063 | 2039-01-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |